Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers July 31, 2015
Pharmacy Choice - News - Over-the-Counter Drugs - July 31, 2015

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 33     Next >>     Go To Page:

7/31/15 - Ipsen: 2015 Half-Year Results
The Board of Directors of Ipsen, chaired by Marc de Garidel, met on 30 July 2015 to approve the financial statements for the first half 2015, published today. *As of 30 June 2014, net closing cash included? 80 m withdrawn from the syndicated credit facility. Commenting on the first half 2015 performance, Marc de Garidel, Chairman and Chief Execut
7/30/15 - Allergan Confirms Generic Tyvaso Patent Challenge
Allergan's ANDA product is a generic version of United Therapeutics Corporation's Tyvaso , which is indicated for the treatment of pulmonary arterial hypertension to improve exercise ability. United Therapeutics filed suit against Allergan on July 22, 2015 in the U.S. District Court for the District of New Jersey seeking to prevent Allergan from.
7/30/15 - EU Approves Mylan's Acquisition Of Perrigo
BRUSSELS- The European Commission Wednesday said it has approved the acquisition of Perrigo of Ireland by Mylan of the Netherlands, under the EU Merger Regulation. Perrigo is specialized in selling over-the-counter drugs, available without prescription in pharmacies. In the limited instances where both Mylan and Perrigo sell pharmaceutical products
7/30/15 - Onxeo Reports First Half 2015 Business Update and Consolidated Accounts
The first half year of 2015 has been extremely active for Onxeo. In parallel, Onxeo has been particularly active focusing on elevated scientific exchange, with an increased visibility at several key medical congresses devoted to oncology, including two posters presented at the American Society of Clinical Oncology Annual Meeting. We strongly bel
7/30/15 - Regulators Pushing For Healthier Foods Creates Opportunity for Growth Stocks
REDONDO BEACH, CA/ ACCESSWIRE/ July 30, 2015/ With the global population surging to 7.3 billion people, there is a clear need for more food in the future. Regulators in the U.S. Food and Drug Administration have taken steps to curtail drug usage in animal feed for growth promotion, a move meant to try and curb the breeding of antibiotic-resistance
7/29/15 - Bayer profits jump in second quarter [Daily News Egypt]
German pharmaceutical giant Bayer has posted a surprising jump in net profit for the second quarter, lifted by strong currency effects and gains in its health care, specialty plastics and agricultural chemicals sectors. Bayer on Wednesday logged a 21 percent on-the-year rise in net profit in the second quarter of 2015. The gains brought the Leverku
7/29/15 - DCGI to find how online sale of drugs can be allowed [DNA : Daily News & Analysis (India)]
The Drugs Controller General of India hopes to answer this. dna had first reported about the rampant internet pharmacy racket and its modus operandi, where prescription drugs were being illegally exported from India- based suppliers and courier services. State FDA had investigated Snapdeal, Flipkart and Amazon and served them show-cause notices, as
7/29/15 - Global API Market to Be Hampered by Stern Regulatory Policies in European Union: Transparency Market Research
Active Pharmaceutical Ingredients Market:- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014- 2020 Albany, NY 07/29/2015 The recent patent expiry of several blockbuster drugs has presented specialized active pharmaceutical ingredients manufacturers with ample opportunities for expansion all over the world. FDA defines AP
7/29/15 - Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review
Naloxone nasal spray is expected to be the first FDA- approved intranasal naloxone product indicated to treat opioid overdose in the United States. "As the rate of opioid overdoses and their profound impact on communities nationwide continues to rise, naloxone nasal spray may help make every life-saving second count by potentially allowing anyone-
7/29/15 - Marin: Drug firms must pay for pill disposal [The Marin Independent Journal, Novato, Calif.]
July 29 Marin County officials launched a new front in the war on prescription drug abuse Tuesday, saying pharmaceutical firms should pay for the safe disposal of old pills and medications. A spokeswoman for the California Retailers Association pledged cooperation. The board agreed with Supervisor Katie Rice, who called the measure a model of col
7/29/15 - Mylan gets European clearance in proposed Perrigo takeover
Mylan NV said Wednesday that it received European regulatory approval to move forward with its proposed buyout of Perrigo Co., which has resisted repeated overtures. In April, the generic drugmaker raised its offer for Perrigo to $232.23, or about $34.1 billion, in cash and stock. But Dublin- based Perrigo, which makes over-the-counter medicines
7/29/15 - Picked Out A Coffin Yet? Take Ibuprofen And Die OpEd [Eurasia Review]
In case you missed it: The FDA has just issued a warning on various prescription and non-prescription drugs that Americans ingest by the boatload. Here's a blurb from the FDA website:. "FDA is strengthening an existing warning in prescription drug labels and over-the-counter Drug Facts labels to indicate that nonsteroidal anti-inflammatory drugs c
7/29/15 - Teenage use of over-the-counter morning-after pill doubles in a decade
The report comes from a Centers for Disease Control and Prevention survey, which monitored sexual activity and contraceptive use among about 2,000 US teens aged 15 to 19 from 2011 to 2013.. In 2013, the Food and Drug Administration approved the emergency contraceptive Plan B One-Step for use without a prescription or age restrictions. Typically cos
7/28/15 - FDA Accepts OPKO's New Drug Application for Rayaldee?
OPKO Health, Inc. today announced that the U.S. Food and Drug Administration has accepted for review OPKO s New Drug Application for calcifediol modified-release capsules. Kevin J. Martin, Director of the Division of Nephrology at Saint Louis University School of Medicine. If approved, Rayaldee will provide a new therapeutic option for contro
Pfizer Inc. reported financial results for second-quarter 2015 and announced increases to the midpoints of its 2015 financial guidance ranges for reported revenues and reported and adjusted diluted EPS. The Innovative Products business is composed of two operating segments: the Global Innovative Pharmaceutical segment and the Global Vaccines,...
7/28/15 - Teva CEO: Allergan acquisition a game changer [Globes, Tel Aviv, Israel]
July 28 "The acquisition of the generic division of Allergan is a game changer. It puts Teva Pharmaceutical Industries Ltd. in a position where it can once again change the rules of the generic game, "Teva president and CEO Erez Vigodman said today in a talk with" Globes, "after the company announced its acquisition of Allergan's generic division
7/27/15 - Allergan Accelerates Transformation to Branded Growth Pharma Leader by Divesting Global Generics Business to Teva for $40.5 Billion
Allergan plc today announced that it has entered into a definitive agreement under which Teva Pharmaceutical Industries Ltd. will acquire Allergan's global generic pharmaceuticals business for $40.5 billion. Allergan will receive $33.75 billion in cash and $6.75 billion in Teva stock. In addition, Allergan retains 50 percent of Teva's future econ
7/27/15 - Analysts expect more tie-ups in generic drug business
The Dutch drugmaker Mylan, which had resisted Teva's advances for three months, is pressing ahead with its offer for Irish drug and ingredients maker Perrigo. Perrigo has turned down Mylan's offer. If they can't work it out, Perrigo might find other suitors as the competitive generic drug industry keeps consolidating.
7/27/15 - Civilian Health and Medical Program of the Uniformed Services (CHAMPUS)/TRICARE: TRICARE Pharmacy Benefits Program
Document Number: "Docket ID: DOD -2012- HA-0049". EFFECTIVE DATE: This final rule is effective August 26, 2015. George E. Jones, Jr., Chief, Pharmacy Operations Division, Defense Health Agency, telephone 703-681-2890..
7/27/15 - DOD Issues Final Rule on Over-the-Counter Drug Program
WASHINGTON, July 27 The Department of Defense published the following rule in the Federal Register:. Civilian Health and Medical Program of the Uniformed Services/ TRICARE: TRICARE Pharmacy Benefits Program. A Rule by the Defense Department on 07/27/2015.
7/27/15 - FDA strengthens warning on NSAID labels
By a News Reporter-Staff News Editor at Pharma Business Week The U.S. Food and Drug Administration announced that it is strengthening an existing label warning that non-aspirin nonsteroidal anti-inflammatory drugs increase the chance of heart attack or stroke. The FDA reached its decision to strengthen NSAID warning labels following a comprehensi
7/27/15 - Israel's Teva buys Allergan generic drug unit for USD 40.5 billion [Cihan News Agency (Turkey)]
KUD?S- Israel's drugmaker Teva, the largest of its kind in the world, announced Monday that it has signed a deal to acquire the generic unit of Irish pharmaceutical company Allergan for 40.5 billion U.S. dollars. The deal will see Allergan receiving 33.75 billion dollars in cash, in addition to shares of Teva valued at 6.75 billion dollars, said a
7/27/15 - Janssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral, Once-Daily OLYSIO (Simeprevir) in Combination with Sofosbuvir
Release date- 24072015- TITUSVILLE, N.J.- Janssen Therapeutics, Division of Janssen Products, LP, today announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration to update the label for once-daily, all-oral OLYSIO. Sofosbuvir is a nucleotide analog NS5B polymerase inhibitor marketed by Gilead Sciences,
7/27/15 - Teva drops bid for Mylan, buys Allergan generic drug company for $40.5 billion [Pittsburgh Post-Gazette]
Mylan's stock fell to $56.68, losing $9.26 a share, after Teva said it had reached a deal to buy Dublin- based Allergan Plc's generics business for cash and stock valued at $40.5 million, roughly the same price it had offered for Mylan. Mylan, which has been fighting Teva's advances, issued a statement congratulating Teva on the Allergan deal and s
7/27/15 - Teva drops bid for Mylan, buys Allergan's generics unit for $40.5 billion [Pittsburgh Post-Gazette]
Mylan's stock fell to $56.68, losing $9.26 a share, after Teva said it had reached a deal to buy Dublin- based Allergan Plc's generics division for cash and stock valued at $40.5 billion, roughly the same price it had offered for Mylan. Mylan, which has been fighting Teva's advances, issued a statement congratulating Teva on the Allergan deal and s
Articles(s): 1 - 25 of 33     Next >>     Go To Page:

© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Pharmacy Spanish
This lesson is supported by:
Hands on Spanish
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement